<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538794</url>
  </required_header>
  <id_info>
    <org_study_id>CDX0159-02</org_study_id>
    <nct_id>NCT04538794</nct_id>
  </id_info>
  <brief_title>A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celldex Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the safety of multiple doses of CDX-0159 in patients with&#xD;
      Chronic Spontaneous Urticaria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to explore the safety, pharmacodynamics, and pharmacokinetics of&#xD;
      ascending doses of CDX-0159 in patients with Chronic Spontaneous Urticaria who remain&#xD;
      symptomatic despite treatment with antihistamines.&#xD;
&#xD;
      There is a screening period of up to 2 weeks, a 12-week double-blind treatment period and a&#xD;
      12-week follow-up period after treatment. Patients will receive multiple doses of CDX-0159 or&#xD;
      placebo as add on therapy to their antihistamine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by the incidence and severity of adverse events</measure>
    <time_frame>From Day 1 (first dose) to Day 169 (last follow-up visit)</time_frame>
    <description>Safety of multiple, ascending doses of CDX-0159 as determined by drug related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation</measure>
    <time_frame>From Day 1 (before first dose) to Day 169 (last follow-up visit)</time_frame>
    <description>CDX-0159 serum concentrations will be measured at specified visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic evaluation</measure>
    <time_frame>From Day 1 (first dose) to Day 169 (last follow-up visit)</time_frame>
    <description>The change from baseline for Urticaria Activity Score (UAS7) in patients who received CDX-0159 vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic evaluation</measure>
    <time_frame>From Day 1 (first dose) to Day 169 (last follow-up visit)</time_frame>
    <description>The change from baseline for Hives Severity Score (HSS7) in patients who received CDX-0159 vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic evaluation</measure>
    <time_frame>From Day 1 (first dose) to Day 169 (last follow-up visit)</time_frame>
    <description>The change from baseline for Itch Severity Score (ISS7) in patients who received CDX-0159 vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic evaluation</measure>
    <time_frame>Day 1 (first dose) to Day 169 (last follow up visit)</time_frame>
    <description>The change in baseline for Urticaria Control Test (UCT) in patients who received CDX-0159 vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic evaluation</measure>
    <time_frame>From Day 1 (before first dose) to Day 169 (last follow-up visit)</time_frame>
    <description>The effect of CDX-0159 on stem cell factor levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic evaluation</measure>
    <time_frame>From Day 1 (before first dose) to Day 169 (last follow-up visit)</time_frame>
    <description>The effect of CDX-0159 on tryptase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>From Day 1 (before dosing) to Day 169 (last follow-up visit)</time_frame>
    <description>Assessment of immunogenicity by measuring the development of anti- CDX-0159 antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Spontaneous Urticaria</condition>
  <arm_group>
    <arm_group_label>CDX-0159</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDX-0159 every 4-8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline every 4-8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-0159</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>CDX-0159</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Males and females, 18 - 75 years old.&#xD;
&#xD;
          2. Diagnosis of chronic spontaneous urticaria (CSU) despite the use of H1-antihistamines&#xD;
             alone or in combination with H2-antihistamines and/or leukotriene receptor&#xD;
             antagonists, as defined by:&#xD;
&#xD;
               1. Diagnosis of CSU for &gt;/= 6 months.&#xD;
&#xD;
               2. The presence of itch and hives for &gt;/= 6 consecutive weeks at any time prior to&#xD;
                  Visit 1 despite current use of H1-antihistamines.&#xD;
&#xD;
               3. UAS7 of &gt;/= 16 and HSS7 of &gt;/= 8 during the 7 days before treatment&#xD;
&#xD;
               4. In-clinic UAS &gt;/= 4 on one of the screening visit days&#xD;
&#xD;
               5. Use of H1-antihistamines alone or in combination with H2-antihistamines and/or&#xD;
                  leukotriene receptor antagonists for at least 3 days immediately prior to study&#xD;
                  entry and throughout the study.&#xD;
&#xD;
          3. Other than CSU, have no other significant medical conditions that would cause&#xD;
             additional risk or interfere with study procedures.&#xD;
&#xD;
          4. Normal blood counts and liver function tests.&#xD;
&#xD;
          5. Both males and females of child-bearing potential must agree to use highly effective&#xD;
             contraceptives during the study and for 150 days afterwards after treatment.&#xD;
&#xD;
          6. Willing and able to complete a daily symptom electronic diary for the duration of the&#xD;
             study and adhere to the study visit schedule.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or nursing.&#xD;
&#xD;
          2. Cleary defined cause for chronic urticaria.&#xD;
&#xD;
          3. Known HIV, hepatitis B or hepatitis C infection.&#xD;
&#xD;
          4. Vaccination with a live vaccine within 4 weeks prior to study drug administration&#xD;
             (subjects must agree to avoid vaccination during the study). Inactivated vaccines are&#xD;
             allowed such as seasonal influenza for injection.&#xD;
&#xD;
          5. History of anaphylaxis.&#xD;
&#xD;
        There are additional criteria that your study doctor will review with you to confirm you&#xD;
        are eligible for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celldex Therapeutics</last_name>
    <phone>844-723-9363</phone>
    <email>info@celldex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Center of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Honeycutt</last_name>
      <phone>205-209-4186</phone>
      <email>choneycutt@alabamaallergy.com</email>
    </contact>
    <contact_backup>
      <last_name>Charles Bower</last_name>
      <phone>205-209-4178</phone>
      <email>cbower@alabamaallergy.com</email>
    </contact_backup>
    <investigator>
      <last_name>John Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Allergy &amp; Immunology Research</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal Jain, MD</last_name>
      <phone>480-626-6600</phone>
      <phone_ext>116</phone_ext>
      <email>njain@santanallergy.com</email>
    </contact>
    <contact_backup>
      <last_name>Marguerite Abrahamson</last_name>
      <phone>480-626-6600</phone>
      <phone_ext>116</phone_ext>
      <email>mabrahamson@santanallergy.com</email>
    </contact_backup>
    <investigator>
      <last_name>Neal Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarasota Clinical Research</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Kastes, RN</last_name>
      <phone>941-927-4888</phone>
      <email>research@windomallergy.com</email>
    </contact>
    <investigator>
      <last_name>Hugh H Windom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth B Forman</last_name>
      <email>sforman@forcaremed.com</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Deluca</last_name>
      <email>bdeluca@forcaremed.com</email>
    </contact_backup>
    <investigator>
      <last_name>Seth B Forman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Treasure Valley Medical Research</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Gonzales</last_name>
      <email>sgonzales@tvmedresearch.com</email>
    </contact>
    <investigator>
      <last_name>Neetu Talreja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry Evans, APRN</last_name>
      <phone>513-354-1760</phone>
      <email>sevans@bernsteincrc.com</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Bernstein, MD</last_name>
      <email>jbernstein@bernsteincrc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Allergy and Asthma Research, LLC</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faye Singleton, CRC</last_name>
      <phone>843-576-3382</phone>
      <email>fsingleton@nationalallergyandent.com</email>
    </contact>
    <contact_backup>
      <last_name>John T Ramey, MD</last_name>
      <phone>843-797-8162</phone>
      <email>Drramey@nationalallergyandent.com</email>
    </contact_backup>
    <investigator>
      <last_name>John T Ramey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AARA Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalea Aguilar, CCRC</last_name>
      <phone>214-365-0365</phone>
      <phone_ext>153</phone_ext>
      <email>Daguilar@AARAResearch.com</email>
    </contact>
    <investigator>
      <last_name>William R Lumry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite University</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Maurer, Prof.</last_name>
      <email>marcus.maurer@charite.de</email>
    </contact>
    <investigator>
      <last_name>Marcus Maurer, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDX-0159</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Chronic Urticaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

